Equities Analysts Offer Predictions for biote Q1 Earnings

biote Corp. (NASDAQ:BTMD) – Analysts at Roth Capital dropped their Q1 2025 earnings per share estimates for shares of biote in a research note issued to investors on Thursday, March 13th. Roth Capital analyst G. Kelly now anticipates that the company will post earnings of $0.09 per share for the quarter, down from their previous estimate of $0.13. The consensus estimate for biote’s current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote’s Q2 2025 earnings at $0.12 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.16 EPS, FY2025 earnings at $0.53 EPS and FY2026 earnings at $0.70 EPS.

Separately, Craig Hallum reduced their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday.

biote Trading Up 22.5 %

Shares of NASDAQ BTMD opened at $3.76 on Friday. biote has a 12 month low of $3.04 and a 12 month high of $8.44. The stock has a 50 day moving average of $4.96 and a 200-day moving average of $5.55. The company has a market capitalization of $204.31 million, a P/E ratio of 14.46 and a beta of 1.07.

Institutional Trading of biote

Several large investors have recently modified their holdings of BTMD. Victory Capital Management Inc. acquired a new stake in shares of biote during the 3rd quarter worth $106,000. MetLife Investment Management LLC lifted its position in shares of biote by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after buying an additional 9,343 shares during the last quarter. Wasatch Advisors LP lifted its position in shares of biote by 8.4% during the 3rd quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock worth $7,772,000 after buying an additional 107,792 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its position in biote by 24.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock valued at $1,520,000 after purchasing an additional 54,302 shares during the last quarter. Finally, Quarry LP bought a new position in biote in the third quarter valued at about $104,000. 21.68% of the stock is owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.